Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 16

Results For "2025"

1125 News Found

Incyte eyes first-line nod for Tafasitamab in aggressive lymphoma
News | January 07, 2026

Incyte eyes first-line nod for Tafasitamab in aggressive lymphoma

Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma (NHL) in adults, represents 40% of all cases worldwide


Wegovy pill marks first GLP-1 weight-loss medicine in oral form
News | January 06, 2026

Wegovy pill marks first GLP-1 weight-loss medicine in oral form

The approval introduces a needle-free alternative to injectable GLP-1 therapies


Dabur sees early demand recovery, rural sales lead growth in Q3 FY26
News | January 06, 2026

Dabur sees early demand recovery, rural sales lead growth in Q3 FY26

Within India, Dabur expects its Home & Personal Care business to deliver double-digit growth,


Jaguar Health wins $240,000 FDA grant to advance dog cancer diarrhea treatment
News | January 05, 2026

Jaguar Health wins $240,000 FDA grant to advance dog cancer diarrhea treatment

The company said it received notice on January 1 from the FDA’s Center for Veterinary Medicine that the funding will support its ongoing effectiveness study of Canalevia-CA1


Exports of AYUSH and herbal products touches US$ 689 million in 2024–25
News | January 05, 2026

Exports of AYUSH and herbal products touches US$ 689 million in 2024–25

India’s traditional medicine systems have also earned formal recognition in key bilateral trade agreements


AstraZeneca elevates Vikram Chand as SVP, Head of R&D for Japan
People | January 04, 2026

AstraZeneca elevates Vikram Chand as SVP, Head of R&D for Japan

Dr. Chand held several leadership positions within AstraZeneca and the broader biopharmaceutical industry


Indian Pharmacopoeia 2026 debuts with 121 new monographs targeting TB, diabetes, and cancer
News | January 04, 2026

Indian Pharmacopoeia 2026 debuts with 121 new monographs targeting TB, diabetes, and cancer

Coverage has been significantly strengthened across key therapeutic categories, including anti-tubercular, anti-diabetic and anti-cancer medicines, as well as iron supplements, thereby ensuring more comprehensive standardisation of medicines used under various National Health Programmes


Caplin Point Labs acquires 10 ANDAs, targets $473M US market
News | January 03, 2026

Caplin Point Labs acquires 10 ANDAs, targets $473M US market

The portfolio, purchased from a leading multinational generic manufacturer, addresses a market valued at $473.2 million for the 12 months ending August 2025


CORONA Remedies posts double-digit growth in Q2, H1 FY26; PAT surges up to 35%
News | January 03, 2026

CORONA Remedies posts double-digit growth in Q2, H1 FY26; PAT surges up to 35%

The company’s consolidated revenue from operations rose to Rs. 361.13 crore in Q2 FY26 and Rs. 707.67 crore for the first half


Cupid reports record Q3, eyes GCC expansion with Saudi FMCG facility
News | January 03, 2026

Cupid reports record Q3, eyes GCC expansion with Saudi FMCG facility

Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity